January 23, 2026

Upstream Bio, Inc. (UPB) Stock Analysis: Potential 49.64% Upside Amid Strong Buy Ratings

Investors seeking opportunities in the biotechnology sector may find Upstream Bio, Inc. (UPB) an intriguing prospect. As a clinical-stage biotech company, Upstream Bio focuses on the..

Tilray Brands, Inc. (TLRY) Stock Analysis: Exploring a Potential 28% Upside in the Cannabis Sector

Tilray Brands, Inc. (NASDAQ: TLRY), a key player in the global cannabis industry, presents a unique investment opportunity with its expansive portfolio and international reach. With..

Ardelyx, Inc. (ARDX) Stock Analysis: Unpacking a 70% Potential Upside in the Biotech Sector

Ardelyx, Inc. (NASDAQ: ARDX), a biotech company listed on the NASDAQ exchange, is making waves in the healthcare sector with its innovative approach to addressing unmet..

uniQure N.V. (QURE) Stock Analysis: Uncovering a 143.91% Potential Upside in the Biotech Sector

uniQure N.V. (NASDAQ: QURE) is a shining beacon in the biotechnology industry, captivating investors with its innovative approach to treating rare and devastating diseases. Based in..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Strong Buy Ratings Amid Potential 7% Upside

Maze Therapeutics, Inc. (MAZE), a burgeoning player in the biotechnology sector, is captivating investor attention with its robust pipeline of precision medicines targeting renal and cardiovascular..

Personalis, Inc. (PSNL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations

Personalis, Inc. (NASDAQ: PSNL), a key player in the healthcare sector’s diagnostics and research industry, is at a critical juncture. With a market capitalization just shy..

Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotech Frontier with Potential Upside

Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company that has carved a niche in the healthcare sector by focusing on innovative protein degradation therapies. Headquartered..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Promising 315% Potential Upside in Biotechnology

Investors with a keen eye on the biotechnology sector may find Anavex Life Sciences Corp. (NASDAQ: AVXL) an intriguing prospect. Positioned in the healthcare industry, Anavex..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 46% Potential Upside for Investors

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a dynamic player in the biotechnology sector, is capturing investor attention with its compelling 46.42% potential upside, as suggested by..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with 90% Upside Potential

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is making waves in the biotechnology sector with a compelling growth narrative. As a commercial-stage company, Day One is dedicated..

Standard BioTools Inc. (LAB) Stock Analysis: Navigating the -3.73% Potential Downside in a Competitive Medical Device Landscape

Investors with an eye on the healthcare sector, particularly those focused on medical devices, might find Standard BioTools Inc. (NASDAQ: LAB) an intriguing subject of analysis...

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 112.50% Potential Upside in the Healthcare Sector

Organogenesis Holdings Inc. (NASDAQ: ORGO), a notable player in the regenerative medicine landscape, is capturing investor attention with a striking potential upside of 112.50%. As the..

COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a 135.88% Potential Upside in Mental Health Innovation

COMPASS Pathways Plc (NASDAQ: CMPS) is currently capturing the attention of investors with its promising advancements in mental health treatments and an intriguing potential upside of..

Verastem, Inc. (VSTM) Stock Analysis: Exploring a 141% Potential Upside in the Promising Biotech Sector

Verastem, Inc. (NASDAQ: VSTM), a U.S.-based biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to cancer treatment. As a development-stage company,..

Gyre Therapeutics, Inc. (GYRE) Investor Outlook: A Potential 123% Upside in the Biotech Space

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a pioneering biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to tackling organ fibrosis through small-molecule..

MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a Potential 42.85% Upside in Biotech Innovation

MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies, is garnering significant attention from investors due to its promising pipeline and potential..

Kura Oncology, Inc. (KURA) Rating Update: 258% Potential Upside Highlights Growth Potential in Biotech Sector

Kura Oncology, Inc. (NASDAQ: KURA), a prominent player in the biotech sector, continues to capture investor attention with its promising pipeline of cancer therapies. Headquartered in..

Neuropace, Inc. (NPCE) Stock Analysis: A 12.97% Potential Upside with Strong Buy Ratings

Neuropace, Inc. (NASDAQ: NPCE), a pioneering company in the medical device sector, is capturing investor attention with its innovative solutions in the treatment of drug-resistant focal..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside

AbCellera Biologics Inc. (NASDAQ: ABCL), a Canadian biotechnology firm, presents an exciting opportunity for investors in the healthcare sector with a remarkable potential upside of 111.93%...

EyePoint, Inc. (EYPT) Stock Analysis: Unpacking the 120.9% Potential Upside

EyePoint, Inc. (NASDAQ: EYPT), a dynamic player in the biotechnology sector, has captured investor attention with a promising 120.9% potential upside, according to analyst ratings. Specializing..

Search

Funds

January 23, 2026

Search

Funds

January 23, 2026

FTSE 100

Funds